UNSPSC 51162004: Aminophylline/ephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162004 Aminophylline/ephedrine is a Commodity code that in recent state and local activity appears substantially misaligned with its nominal scope — the posted opportunities show state and local governments procuring naloxone, pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products, none of which are aminophylline or ephedrine products. Issuing bodies across the recent opportunities include a county health department (Seminole County, Florida), a county government employer health plan (Hall County, Georgia), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). The code shows little relevant recent activity aligned to its intended pharmaceutical scope.

Geographically, the recent opportunities are distributed across Florida, Georgia, Texas, Minnesota, and Oregon, with no concentration in any single region. Representative recent solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for naloxone and drug deactivation systems; Hall County's RFQ/P #47-010 (posted May 4, 2026, due June 4, 2026) for on-site pharmacy services; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) on direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products. The mismatch between the code's nominal scope and the actual work being solicited suggests that business development pursuit under this code should be informed by clarification of whether aminophylline or ephedrine products are the intended target or whether the tagging reflects a broader pharmaceutical procurement category that encompasses multiple drug classes.